<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37605254</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2523-3106</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Advances in rheumatology (London, England)</Title><ISOAbbreviation>Adv Rheumatol</ISOAbbreviation></Journal><ArticleTitle>TP53 and p21 (CDKN1A) polymorphisms and the risk of systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>43</StartPage><MedlinePgn>43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s42358-023-00320-4</ELocationID><Abstract><AbstractText Label="BACKGROUND">The p53 and p21 proteins are important regulators of cell cycle and apoptosis and may contribute to autoimmune diseases, such as systemic lupus erythematosus (SLE). As genetic polymorphisms may cause changes in protein levels and functions, we investigated associations of TP53 and p21 (CDKN1A) polymorphisms (p53 72 G&#x2009;&gt;&#x2009;C-rs1042522; p53 PIN3-rs17878362; p21 31 C&#x2009;&gt;&#x2009;A-rs1801270; p21 70 C&#x2009;&gt;&#x2009;T-rs1059234) with the development of systemic lupus erythematosus (SLE) in a Southeastern Brazilian population.</AbstractText><AbstractText Label="METHODS">Genotyping of 353 female volunteers (cases, n&#x2009;=&#x2009;145; controls, n&#x2009;=&#x2009;208) was performed by polymerase chain reaction, restriction fragment length polymorphism and/or DNA sequencing. Associations between TP53 and p21 polymorphisms and SLE susceptibility and clinical manifestations of SLE patients were assessed by logistic regression analysis.</AbstractText><AbstractText Label="RESULTS">Protective effect was observed for the genotype combinations p53 PIN3 A1/A1-p21 31 C/A, in the total study population (OR 0.45), and p53 PIN3 A1/A2-p21 31 C/C, in non-white women (OR 0.28). In Whites, p53 72 C-containing (OR 3.06) and p53 PIN3 A2-containing (OR 6.93) genotypes were associated with SLE risk, and higher OR value was observed for the combined genotype p53 72 G/C-p53 PIN3 A1/A2 (OR 9.00). Further, p53 PIN3 A1/A2 genotype was associated with serositis (OR 2.82), while p53 PIN3 A2/A2 and p53 72 C/C genotypes were associated with neurological disorders (OR 4.69 and OR 3.34, respectively).</AbstractText><AbstractText Label="CONCLUSIONS">Our findings showed that the TP53 and p21 polymorphisms included in this study may have potential to emerge as SLE susceptibility markers for specific groups of patients. Significant interactions of the TP53 polymorphisms with serositis and neurological disorders were also observed in SLE patients.</AbstractText><CopyrightInformation>&#xa9; 2023. Sociedade Brasileira de Reumatologia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Macedo</LastName><ForeName>Jacyara Maria Brito</ForeName><Initials>JMB</Initials><Identifier Source="ORCID">0000-0002-4976-9318</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, State University of Rio de Janeiro - UERJ, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Amanda Lima</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0002-2143-4719</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, State University of Rio de Janeiro - UERJ, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Amanda Chaves</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-4372-096X</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, State University of Rio de Janeiro - UERJ, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landeira</LastName><ForeName>Leandro Ferreira Lopes</ForeName><Initials>LFL</Initials><Identifier Source="ORCID">0000-0001-5121-8139</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, State University of Rio de Janeiro - UERJ, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portari</LastName><ForeName>Elyzabeth Avvad</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0003-2372-0898</Identifier><AffiliationInfo><Affiliation>Department of Pathological Anatomy, State University of Rio de Janeiro - UERJ, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Fernandes Figueira Institute - FIOCRUZ, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos-Rebou&#xe7;as</LastName><ForeName>Cintia Barros</ForeName><Initials>CB</Initials><Identifier Source="ORCID">0000-0003-4729-2373</Identifier><AffiliationInfo><Affiliation>Department of Pathological Anatomy, State University of Rio de Janeiro - UERJ, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klumb</LastName><ForeName>Evandro Mendes</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0001-9546-3144</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Pedro Ernesto University Hospital, State University of Rio de Janeiro - UERJ, Boulevard 28 de Setembro, 87, Vila Isabel, Rio de Janeiro, RJ, CEP 20551-030, Brazil. klumb@uol.com.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Adv Rheumatol</MedlineTA><NlmUniqueID>101734172</NlmUniqueID><ISSNLinking>2523-3106</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493956">CDKN1A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050759" MajorTopicYN="Y">Cyclin-Dependent Kinase Inhibitor p21</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012700" MajorTopicYN="N">Serositis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016159" MajorTopicYN="Y">Tumor Suppressor Protein p53</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Genetic polymorphisms</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">TP53</Keyword><Keyword MajorTopicYN="N">p21</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37605254</ArticleId><ArticleId IdType="doi">10.1186/s42358-023-00320-4</ArticleId><ArticleId IdType="pii">10.1186/s42358-023-00320-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Balomenos D. Cell cycle regulation and systemic lupus erythematosus. In: Lahita RG, editor. Systemic lupus erythematosus. 5th ed. London: Academic Press; 2011. p. 191&#x2013;8. https://doi.org/10.1016/B978-0-12-374994-9.10011-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-374994-9.10011-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharabi A, Tsokos GC. T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nat Rev Rheumatol. 2020;16:100&#x2013;12. https://doi.org/10.1038/s41584-019-0356-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-019-0356-x</ArticleId><ArticleId IdType="pubmed">31949287</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L, Lu MP, Wang JH, Xu M, Yang SR. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr. 2020;16:19&#x2013;30. https://doi.org/10.1007/s12519-019-00229-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-019-00229-3</ArticleId><ArticleId IdType="pubmed">30796732</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Kaplan MJ. The role of neutrophils and NETosis in autoimmune and renal diseases. Nat Rev Nephrol. 2016;12:402&#x2013;13. https://doi.org/10.1038/nrneph.2016.71 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2016.71</ArticleId><ArticleId IdType="pubmed">27241241</ArticleId><ArticleId IdType="pmc">5510606</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaipl US, Munoz LE, Grossmayer G, Lauber K, Franz S, Sarter K, et al. Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun. 2007;28:114&#x2013;21. https://doi.org/10.1016/j.jaut.2007.02.005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2007.02.005</ArticleId><ArticleId IdType="pubmed">17368845</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Wei W, Liu ML. Extracellular vesicles and lupus nephritis&#x2014;new insights into pathophysiology and clinical implications. J Autoimmun. 2020;115:102540. https://doi.org/10.1016/j.jaut.2020.102540 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102540</ArticleId><ArticleId IdType="pubmed">32893081</ArticleId><ArticleId IdType="pmc">9107953</ArticleId></ArticleIdList></Reference><Reference><Citation>Takatori H, Kawashima H, Suzuki K, Nakajima H. Role of p53 in systemic autoimmune diseases. Crit Rev Immunol. 2014;34:509&#x2013;16. https://doi.org/10.1615/CritRevImmunol.2014012193 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/CritRevImmunol.2014012193</ArticleId><ArticleId IdType="pubmed">25597313</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs B, Patel A, Hershey JN, Dennis GJ, Kirschfink M, Tsokos GC. Antibodies against p53 in sera from patients with systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 1997;40:980&#x2013;2. https://doi.org/10.1002/art.1780400531 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400531</ArticleId><ArticleId IdType="pubmed">9153564</ArticleId></ArticleIdList></Reference><Reference><Citation>Joruiz SM, Bourdon JC. p53 isoforms: key regulators of the cell fate decision. Cold Spring Harb Perspect Med. 2016;6:a026039. https://doi.org/10.1101/cshperspect.a026039 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a026039</ArticleId><ArticleId IdType="pubmed">26801896</ArticleId><ArticleId IdType="pmc">4968168</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J, et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat. 2016;37:865&#x2013;76. https://doi.org/10.1002/humu.23035 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.23035</ArticleId><ArticleId IdType="pubmed">27328919</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092&#x2013;100. https://doi.org/10.1128/mcb.19.2.1092 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mcb.19.2.1092</ArticleId><ArticleId IdType="pubmed">9891044</ArticleId><ArticleId IdType="pmc">116039</ArticleId></ArticleIdList></Reference><Reference><Citation>Senturk E, Manfredi JJ. p53 and cell cycle effects after DNA damage. Methods Mol Biol. 2013;962:49&#x2013;61. https://doi.org/10.1007/978-1-62703-236-0_4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-62703-236-0_4</ArticleId><ArticleId IdType="pubmed">23150436</ArticleId><ArticleId IdType="pmc">4712920</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Guti&#xe9;rrez-Enr&#xed;quez S, et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene. 2004;23:1954&#x2013;6. https://doi.org/10.1038/sj.onc.1207305 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1207305</ArticleId><ArticleId IdType="pubmed">14647431</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson BR, Baccala R, Song J, Croft M, Kono DH, Theofilopoulos AN. Deficiency of the cyclin kinase inhibitor p21(WAF-1/CIP-1) promotes apoptosis of activated/memory T cells and inhibits spontaneous systemic autoimmunity. J Exp Med. 2004;199:547&#x2013;57. https://doi.org/10.1084/jem.20031685 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20031685</ArticleId><ArticleId IdType="pubmed">14970181</ArticleId><ArticleId IdType="pmc">2211831</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong EK, Chong WP, Wong WH, Lau CS, Chan TM, Ng PK, et al. p21 gene polymorphisms in systemic lupus erythematosus. Rheumatology (Oxford). 2007;46:220&#x2013;6. https://doi.org/10.1093/rheumatology/kel210 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kel210</ArticleId><ArticleId IdType="pubmed">16837471</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppresion. Cell. 1993;75:817&#x2013;25. https://doi.org/10.1016/0092-8674(93)90500-P .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(93)90500-P</ArticleId><ArticleId IdType="pubmed">8242752</ArticleId></ArticleIdList></Reference><Reference><Citation>Santiago-Raber ML, Lawson BR, Dummer W, Barnhouse M, Koundouris S, Wilson CB, et al. Role of cyclin kinase inhibitor p21 in systemic autoimmunity. J Immunol. 2001;67:4067&#x2013;74. https://doi.org/10.4049/jimmunol.167.7.4067 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.167.7.4067</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Liu Z, Sturgis EM, Shi Q, Chamberlain RM, Spitz MR, Wei Q. Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2005;26:1596&#x2013;602. https://doi.org/10.1093/carcin/bgi105 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/bgi105</ArticleId><ArticleId IdType="pubmed">15878916</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Zhu JM, Wu S, Li J, Wang MR, Wang TT, Lu YW. Association study between the TP53 rs1042522G/C polymorphism and susceptibility to systemic lupus erythematosus in a Chinese Han population. Rheumatol Int. 2017;37:523&#x2013;9. https://doi.org/10.1007/s00296-017-3662-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-017-3662-0</ArticleId><ArticleId IdType="pubmed">28184992</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. https://doi.org/10.1002/art.1780400928 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Pena SD, Di Pietro G, Fuchshuber-Moraes M, Genro JP, Hutz MH, Kehdy FS, et al. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS ONE. 2011;6:e17063. https://doi.org/10.1371/journal.pone.0017063 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0017063</ArticleId><ArticleId IdType="pubmed">21359226</ArticleId><ArticleId IdType="pmc">3040205</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas-Torres SL, Portari EA, Klumb EM, Guillobel HCR, Camargo MJ, Russomano FB, et al. Association of CDKN2A polymorphisms with the severity of cervical neoplasia in a Brazilian population. Biomarkers. 2014;19:121&#x2013;7. https://doi.org/10.3109/1354750X.2014.881419 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/1354750X.2014.881419</ArticleId><ArticleId IdType="pubmed">24491138</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas-Torres SL, Portari EA, Silva AL, Klumb EM, Guillobel HCR, Camargo MJ, et al. Roles of CDKN1A gene polymorphisms (rs1801270 and rs1059234) in the development of cervical neoplasia. Tumour Biol. 2016;37:10469&#x2013;78. https://doi.org/10.1007/s13277-016-4850-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13277-016-4850-3</ArticleId><ArticleId IdType="pubmed">26846214</ArticleId></ArticleIdList></Reference><Reference><Citation>Iniesta R, Guin&#xf3; E, Moreno V. An&#xe1;lisis estad&#xed;stico de polimorfismos gen&#xe9;ticos en estudios epidemiol&#xf3;gicos. Gac Sanit. 2005;19:333&#x2013;41. https://doi.org/10.1157/13078029 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1157/13078029</ArticleId><ArticleId IdType="pubmed">16050971</ArticleId></ArticleIdList></Reference><Reference><Citation>Sol&#xe9; X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22:1928&#x2013;9. https://doi.org/10.1093/bioinformatics/btl26 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btl26</ArticleId><ArticleId IdType="pubmed">16720584</ArticleId></ArticleIdList></Reference><Reference><Citation>Onel KB, Huo D, Hastings D, Fryer-Biggs J, Crow MK, Onel K. Lack of Association of the TP53 Arg72Pro SNP and the MDM2 SNP309 with systemic lupus erythematosus in Caucasian, African American, and Asian children and adults. Lupus. 2009;18:61&#x2013;6. https://doi.org/10.1177/0961203308094558 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203308094558</ArticleId><ArticleId IdType="pubmed">19074170</ArticleId><ArticleId IdType="pmc">2801155</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YH, Rho YH, Choi SJ, Ji JD, Song GG. The functional p53 codon 72 polymorphism is associated with systemic lupus erythematosus. Lupus. 2005;14:842&#x2013;5. https://doi.org/10.1191/0961203305lu2224oa .</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203305lu2224oa</ArticleId><ArticleId IdType="pubmed">16302680</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez E, Sabio JM, Callejas JL, Ram&#xf3;n E, Haro M, Jim&#xe9;nez-Alonso J, et al. Study of a functional polymorphism in the p53 gene in systemic lupus erythematosus: lack of replication in a Spanish population. Lupus. 2006;15:658&#x2013;61. https://doi.org/10.1177/0961203306070986 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203306070986</ArticleId><ArticleId IdType="pubmed">17120592</ArticleId></ArticleIdList></Reference><Reference><Citation>Piotrowski P, Lianeri M, Mostowska M, Wudarski M, Chwalinska-Sadowska H, Jagodzinski PP. Contribution of polymorphism in codon 72 of p53 gene to systemic lupus erythematosus in Poland. Lupus. 2008;17:148&#x2013;51. https://doi.org/10.1177/0961203307084722 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203307084722</ArticleId><ArticleId IdType="pubmed">18250140</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Bae SC, Choi SJ, Ji JD, Song GG. Associations between the p53 codon 72 polymorphisms and susceptibility to systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis. Lupus. 2012;21:430&#x2013;7. https://doi.org/10.1177/0961203311434941 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203311434941</ArticleId><ArticleId IdType="pubmed">22427364</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbosa FB, Cagnin NF, Simioni M, Farias AA, Torres FR, Molck MC, et al. Ancestry informative marker panel to estimate population stratification using genome-wide human array. Ann Hum Genet. 2017;81:225&#x2013;33. https://doi.org/10.1111/ahg.12208 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ahg.12208</ArticleId><ArticleId IdType="pubmed">28895130</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira FDSCF, Guimar&#xe3;es RM, Lucidi AR, Brum DG, Paiva CLA, Alvarenga RMP. A systematic literature review on the European, African and Amerindian genetic ancestry components on Brazilian health outcomes. Sci Rep. 2019;9:8874. https://doi.org/10.1038/s41598-019-45081-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-45081-7</ArticleId><ArticleId IdType="pubmed">31221977</ArticleId><ArticleId IdType="pmc">6586659</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun-Prado K, Petzl-Erler ML. Programmed cell death 1 gene (PDCD1) polymorphism and pemphigus foliaceus (fogo selvagem) disease susceptibility. Genet Mol Biol. 2007;30:314&#x2013;21. https://doi.org/10.1590/S1415-47572007000300003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1415-47572007000300003</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzone R, Zwergel C, Artico M, Taurone S, Ralli M, Greco A, Mai A. The emerging role of epigenetics in human autoimmune disorders. Clin Epigenet. 2019;11:34. https://doi.org/10.1186/s13148-019-0632-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13148-019-0632-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Surace AEA, Hedrich CM. The role of epigenetics in autoimmune/inflammatory disease. Front Immunol. 2019;10:1525. https://doi.org/10.3389/fimmu.2019.01525 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01525</ArticleId><ArticleId IdType="pubmed">31333659</ArticleId><ArticleId IdType="pmc">6620790</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z, Li X, Qu X, He Y, Ring BZ, Song E, Su L. Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. Carcinogenesis. 2010;31:643&#x2013;7. https://doi.org/10.1093/carcin/bgq018 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/bgq018</ArticleId><ArticleId IdType="pubmed">20089604</ArticleId></ArticleIdList></Reference><Reference><Citation>Sucheston L, Witonsky DB, Hastings D, Yildiz O, Clark VJ, Rienzo A, et al. Natural selection and functional genetic variation in the p53 pathway. Hum Mol Genet. 2011;20:1502&#x2013;8. https://doi.org/10.1093/hmg/ddr028 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr028</ArticleId><ArticleId IdType="pubmed">21266458</ArticleId><ArticleId IdType="pmc">3063984</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N, Zhang K, Zhao H. Haplotype-association analysis. Adv Genet. 2008;60:335&#x2013;405. https://doi.org/10.1016/S0065-2660(07)00414-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0065-2660(07)00414-2</ArticleId><ArticleId IdType="pubmed">18358327</ArticleId></ArticleIdList></Reference><Reference><Citation>Chae BS, Shin TY. Immunoregulatory abnormalities of T cells and hyperreactivity of B cells in the in vitro immune response in pristane-induced lupus mice. Arch Pharm Res. 2007;30:191&#x2013;8. https://doi.org/10.1007/BF02977694 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02977694</ArticleId><ArticleId IdType="pubmed">17366741</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H. Autoreactivity in human IgG memory B cells. Immunity. 2007;26:205&#x2013;13. https://doi.org/10.1016/j.immuni.2007.01.009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2007.01.009</ArticleId><ArticleId IdType="pubmed">17306569</ArticleId><ArticleId IdType="pmc">1839941</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamuro D, Sabbatini P, White E, Prendergast GC. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene. 1997;15:887&#x2013;98. https://doi.org/10.1038/sj.onc.1201263 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1201263</ArticleId><ArticleId IdType="pubmed">9285684</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JS, Lim MA, Cho ML, Ryu JG, Moon YM, Jhun JY, et al. p53 controls autoimmune arthritis via STAT-mediated regulation of the Th17 cell/Treg cell balance in mice. Arthritis Rheum. 2013;65:949&#x2013;59. https://doi.org/10.1002/art.37841 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.37841</ArticleId><ArticleId IdType="pubmed">23280308</ArticleId></ArticleIdList></Reference><Reference><Citation>Su L, Sai Y, Fan R, Thurston SW, Miller DP, Zhou W, et al. p53 (codon 72) and p21 (codon 31) polymorphisms alter in vivo mRNA expression of p21. Lung Cancer. 2003;40:259&#x2013;66. https://doi.org/10.1016/S0169-5002(03)00081-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-5002(03)00081-3</ArticleId><ArticleId IdType="pubmed">12781424</ArticleId></ArticleIdList></Reference><Reference><Citation>Arias CF, Ballesteros-Tato A, Garc&#xed;a MI, Mart&#xed;n-Caballero J, Flores JM, Mart&#xed;nez-A C, Balomenos D. p21 CIP1/WAF1 controls proliferation of activated/memory T cells and affects homeostasis and memory T cell responses. J Immunol. 2007;178:2296&#x2013;306. https://doi.org/10.4049/jimmunol.178.4.2296 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.4.2296</ArticleId><ArticleId IdType="pubmed">17277135</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Bae S, An S, Park JK, Kim EM, Hwang SG, Kim WJ, Um HD. Cooperative actions of p21WAF1 and p53 induce slug protein degradation and suppress cell invasion. EMBO Rep. 2014;15:1062&#x2013;8. https://doi.org/10.15252/embr.201438587 .</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201438587</ArticleId><ArticleId IdType="pubmed">25141863</ArticleId><ArticleId IdType="pmc">4253846</ArticleId></ArticleIdList></Reference><Reference><Citation>Engeland K. Cell cycle regulation: p53&#x2013;p21-RB signaling. Cell Death Differ. 2022;29:946&#x2013;60. https://doi.org/10.1038/s41418-022-00988-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-022-00988-z</ArticleId><ArticleId IdType="pubmed">35361964</ArticleId><ArticleId IdType="pmc">9090780</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilernia D, Amin P, Flores J, Stecenko A, Sorscher E. Mutation profiling of the c.1521_1523delCTT (p.Phe508del, F508del) cystic fibrosis transmembrane conductance regulator allele using haplotype-resolved long-read next generation sequencing. Hum Mutat. 2022;43:595&#x2013;603. https://doi.org/10.1002/humu.24352 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.24352</ArticleId><ArticleId IdType="pubmed">35170824</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakita S, Hara M, Kitabatake Y, Kwatani K, Kurahashi, Hashizume R. Experimental method for haplotype phasing across the entire length of chromosome 21 in trisomy 21 cells using a chromosome elimination technique. J Hum Genet. 2022;67:565&#x2013;72. https://doi.org/10.1038/s10038-022-01049-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s10038-022-01049-6</ArticleId><ArticleId IdType="pubmed">35637312</ArticleId><ArticleId IdType="pmc">9510051</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews BS, Arora NS, Shadforth MF, Goldberg SK, Davis JS 4th. The role of immune complexes in the pathogenesis of pleural effusions. Am Rev Respir Dis. 1981;124:115&#x2013;20. https://doi.org/10.1164/arrd.1981.124.2.115 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/arrd.1981.124.2.115</ArticleId><ArticleId IdType="pubmed">7258825</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentham J, Morris DL, Graham DSC, Pinder CL, Tombleson P, Behrens TW. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat Genet. 2015;47:1457&#x2013;64. https://doi.org/10.1038/ng.3434 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3434</ArticleId><ArticleId IdType="pubmed">26502338</ArticleId><ArticleId IdType="pmc">4668589</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebastiani GD, Galeazzi M. Immunogenetic studies on systemic lupus erythematosus. Lupus. 2009;18:878&#x2013;83. https://doi.org/10.1177/0961203309106918 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309106918</ArticleId><ArticleId IdType="pubmed">19671786</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>